This week, FDA announced the membership of a Pharmacy Compounding Advisory Committee . This 14-member  group will provide advice on scientific, technical and medical issues concerning drug compounding under sections 503A (traditional compounders) and 503B (outsourcing facilities) of the Federal Food, Drug and Cosmetic Act.
The members include doctors, pharmacists, public health advocates, and consumer advocacy representatives. ASCRS was disappointed to see that after all the advocacy and outreach to FDA by ASCRS and other ophthalmology groups on drug compounding issues, and the nomination of two ophthalmologists to the committee, no ophthalmologists were selected to participate in this workgroup.
ASCRS plans to continue our advocacy on these compounding issues. As you may recall, we are still waiting on guidance from FDA on how they will handle drug compounding for 503B outsourcing facilities and how they will handle the issue of repackaging. We will update you as soon as there is additional information. If you have any questions, please contact Ashley McGlone  at 703-591-2220.